Articles — Recent
Papers, presentations, reports and more, written in LaTeX and published by our community. Search or browse below.

Montasir's Complete CV
It's best suited for those who will apply abroad for higher studies. Created with the Modern CV template ("banking" style).
Md. Montasir Bin Shams

Resume Suyinyin
Personal CV
Created based on the Modern CV template with the bankingstyle
Su Yinyin

Suman Navaratnarajah's Résumé (Electronic Engineer)
Intern CV
Created based on the Modern CV template
Suman

實驗一 基本測量
目的:
熟悉分析實驗數據的方法,測量並分析誤差。
學習有效數的處理。
了解螺旋測微器(Micrometer)的操作方式並用以測定微小物體的厚度或直徑等。
了解游標尺(Vernier caliper)的操作方式並用以測量塑膠管的深度及內、外徑。
黃雅柔

Fixed Point and Steffensen's Acceleration
Math336 Project
zekeriya

Electrical and Electronics Engineering CV
"ModernCV" CV and Cover Letter
LaTeX Template
Version 1.11 (19/6/14)
This template has been downloaded from:
http://www.LaTeXTemplates.com
Original author:
Xavier Danaux (xdanaux@gmail.com)
License:
CC BY-NC-SA 3.0 (http://creativecommons.org/licenses/by-nc-sa/3.0/)
revathi

Gabi Help
The South Pole...
Caden Feldman-Gubbay

Curriculum Vitae (ENG)
My Curriculum Vitae (English Version)
Andrea Magazzini

Optimal Therapeutic Window Model of Interferon alpha and Imatinib in Combination Therapy in CML Patients
Chronic Myeloid Leukemia is a type of cancer that starts in certain blood-forming cells of the bone marrow. Interferon-\(\alpha\) was once the standard front-line treatment producing remission rates of only 28.3 percent in 1991. After the highly effective drugs first became available in 2001, survival rates have increased immensely. According to the American Cancer Society, one large study of CML patients treated with a drug called imatinib found that about 90 percent of them were still alive 5 years after starting treatment. While imatinib has changed the way oncologists treat CML, remission is common after extended gaps in treatment. In this paper, we will explore the long-term dynamics of CML under treatment through the use of use of theoretical and mathematical components. We closely base our methods upon the approach of Urszula Ledzewicz and Helen Moore. We will introduce our unique model and explain component selections, while we move towards understanding the optimal interactions of imatinib and interferon-\(\alpha\) against dormant and proliferating CML cells. Our future work involving optimal control dynamics will be briefly introduced and further solutions are currently ongoing.
Arianna Kalkandis